Chemclin Diagnostics Co. Ltd. A (688468) - Total Liabilities

Latest as of September 2025: CN¥363.17 Million CNY ≈ $53.14 Million USD

Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has total liabilities worth CN¥363.17 Million CNY (≈ $53.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Chemclin Diagnostics Co. Ltd. A to assess how effectively this company generates cash.

Chemclin Diagnostics Co. Ltd. A - Total Liabilities Trend (2017–2024)

This chart illustrates how Chemclin Diagnostics Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check Chemclin Diagnostics Co. Ltd. A liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Chemclin Diagnostics Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
GMM Pfaudler Limited
NSE:GMMPFAUDLR
India Rs26.48 Billion
HPF Co Ltd
SHE:300350
China CN¥403.44 Million
Cloudberry Clean Energy As
OL:CLOUD
Norway Nkr3.99 Billion
Suncha Technology Co Ltd
SHE:001211
China CN¥982.17 Million
Beijing SunwayWorld Science & Technology Co. Ltd.
SHE:301159
China CN¥173.39 Million
Beijing ZEHO Waterfront Ecological Environment Treatment Co Ltd
SHG:605069
China CN¥2.27 Billion
Fujian Oriental Silver Star Investment Co Ltd
SHG:600753
China CN¥260.46 Million
Hana Tour
KO:039130
Korea ₩490.41 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Chemclin Diagnostics Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688468 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.44 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chemclin Diagnostics Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chemclin Diagnostics Co. Ltd. A (2017–2024)

The table below shows the annual total liabilities of Chemclin Diagnostics Co. Ltd. A from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥415.85 Million
≈ $60.85 Million
-3.68%
2023-12-31 CN¥431.76 Million
≈ $63.18 Million
+105.02%
2022-12-31 CN¥210.59 Million
≈ $30.82 Million
+38.33%
2021-12-31 CN¥152.23 Million
≈ $22.28 Million
+27.43%
2020-12-31 CN¥119.46 Million
≈ $17.48 Million
-5.50%
2019-12-31 CN¥126.42 Million
≈ $18.50 Million
+56.33%
2018-12-31 CN¥80.87 Million
≈ $11.83 Million
+22.24%
2017-12-31 CN¥66.15 Million
≈ $9.68 Million
--

About Chemclin Diagnostics Co. Ltd. A

SHG:688468 China Diagnostics & Research
Market Cap
$439.62 Million
CN¥3.00 Billion CNY
Market Cap Rank
#13220 Global
#4156 in China
Share Price
CN¥7.49
Change (1 day)
+1.08%
52-Week Range
CN¥6.79 - CN¥8.94
All Time High
CN¥27.99
About

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more